Kura Oncology Begins Trial of KO-2806 and Cabozantinib for Kidney Cancer

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, has commenced the first patient dosing with KO-2806, a farnesyl transferase inhibitor (FTI), combined with tyrosine kinase inhibitor (TKI) cabozantinib in Phase 1 of the FIT-001 trial targeting clear cell renal cell carcinoma (ccRCC). This development represents a critical step for KO-2806, happening alongside ongoing dose escalation as a standalone treatment.

The Phase 1 FIT-001 trial is investigating KO-2806's safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor effectiveness, both as a monotherapy and in combination with other targeted treatments. Future plans include combining KO-2806 with adagrasib for treating KRASG12C-mutant non-small cell lung cancer (NSCLC).

Kura's Chief Medical Officer, Stephen Dale, M.D., emphasized that this trial cements their position in developing FTIs and demonstrates the compound's potential when paired with TKIs like cabozantinib to combat resistance mechanisms and enhance antitumor responses. The company aims to broaden KO-2806's use as a combination therapy to optimize antitumor activities and counteract treatment resistance.

Additional details about the FIT-001 study and KO-2806's preclinical data, including its efficacy with various targeted therapies, were discussed at the 2023 AACR-NCI-EORTC conference. Kura's clinical program includes other candidates, such as ziftomenib for acute myeloid leukemia (AML) and tipifarnib for head and neck squamous cell carcinoma, under various clinical trials.

Kura Oncology remains focused on developing precision cancer therapies. The company faces risks such as clinical trial uncertainties, regulatory challenges, and financial dependencies. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!